La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

RhoVac Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Lars Hedbys

Amministratore delegato

SEK 191.6k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	less than a year
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	4yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Lars Hedbys (65 yo)

less than a year

Mandato

SEK 191,610

Compensazione

Mr. Lars Hedbys, Ph. D., served as Director at Hamlet Pharma AB (publ) until 2022. He serves as Independent Chairman of the Board of Directors at Scandinavian ChemoTech AB (publ) since 2020. He serves as D...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Lars Hedbys	Acting CEO & Director	8yrs	SEK 191.61k	Nessun dato
Per Straten	Scientific Advisor & Co-Founder	no data	Nessun dato	Nessun dato
Lars Hockenstrom	Director	3yrs	SEK 191.61k	Nessun dato
Cristina Glad	Director	8yrs	SEK 160.69k	Nessun dato
Gunnar Gardemyr	Chairman	5yrs	SEK 383.22k	Nessun dato
Georg Holländer	Scientific Advisory Board	2.3yrs	Nessun dato	Nessun dato
Anne Ridley	Member of Scientific Advisory Board	2.9yrs	Nessun dato	Nessun dato
Per-Anders Abrahamsson	Scientific advisor	no data	Nessun dato	Nessun dato
Klaus Brasso	Scientific Advisor	no data	Nessun dato	Nessun dato

4.0yrs

Durata media

65.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di RHOVAC sono considerati esperti (durata media dell'incarico 4 anni).

RhoVac Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

No independent directors

RhoVac AB Announces Resignation of Anders Ljungqvist as Board Member

RhoVac AB Appoints Lars Hedbys as Acting CEO, Starting from September 1, 2022

Rhovac AB Announces Resignation of Anders Månsson as CEO

No independent directors

Recent updates

Chosa ApS completed the acquisition of RhoVac AB (NGM:RHOVAC) from M2 Asset Management AB (publ) and others in a reverse merger transaction.

RhoVac AB to Report Fiscal Year 2022 Results on Feb 10, 2023

No independent directors

RhoVac AB Announces Resignation of Anders Ljungqvist as Board Member

RhoVac AB to Report Q3, 2022 Results on Nov 11, 2022

RhoVac AB Appoints Lars Hedbys as Acting CEO, Starting from September 1, 2022

RhoVac AB to Report Q2, 2022 Results on Aug 26, 2022

Rhovac AB Announces Resignation of Anders Månsson as CEO

RhoVac AB's Phase IIb Study in Prostate Cancer , BRaVac, Failed to Meet Its Primary Endpoint

Pre-Clinical Findings Support the Potential Use of RhoVac AB's Drug Candidate, Onilcamotide, Across Several Cancers

No independent directors

RhoVac AB Announces Scientific Publication Supports its Cancer Treatment Method

We're Keeping An Eye On RhoVac's (NGM:RHOVAC) Cash Burn Rate

RhoVac AB Announces Another Clean Interim Safety Review of Clinical Phase IIb Study in Prostate Cancer

RhoVac's Market Research Shows Great Potential for A Cancer Vaccine Preventing Recurrence of Metastatic Disease in Multiple Cancers

Rhovac Announces the Completion of Patient Recruitment for the Bravac Clinical Phase Iib Study of Rv001 in Prostate Cancer

RhoVac (NGM:RHOVAC) Is In A Good Position To Deliver On Growth Plans

RhoVac AB Receives Approval to Initiate a Long-Term Follow-Up of Clinical Phase I/II Patients

Is RhoVac (NGM:RHOVAC) In A Good Position To Deliver On Growth Plans?

Rhovac AB Announces the Initiation of First New US Clinic in Company's Phase IIb Study

New 90-day low: kr21.00

Global Covid-19 Vaccination Roll-Out Causes Delay to Rhovac's Phase IIb Study

RhoVac AB Announces First patient in treatment in RhoVac's clinical phase IIb study in United Kingdom

We Think RhoVac (NGM:RHOVAC) Can Easily Afford To Drive Business Growth

New 90-day high: kr21.15

RhoVac's Prostate Cancer Drug Candidate, RV001, is granted Fast Track Designation by the FDA

Rhovac AB Announces That Positive Results from Rhovac's Clinical Phase I/Ii Study Published in Journal of Immunotherapy of Cancer

New 90-day low: kr16.44

RhoVac AB Announces Covid-19 pandemic affecting RhoVac's clinical phase IIb study

New 90-day high: kr20.65

RhoVac AB Announces First Patient in Treatment in Rhovac's Clinical Phase IIb Study in Sweden

RhoVac AB to Report Q2, 2020 Results on Aug 28, 2020

New 90-day high - kr16.98

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Membri del Consiglio di amministrazione

Durata media

Età media